26 December 2020: Database Analysis
Laryngeal Squamous Cell Carcinoma: Potential Molecular Mechanism and Prognostic Signature Based on Immune-Related Genes
Bin-Yu Mo 1BCEF* , Guo-Sheng Li 2BCEF* , Su-Ning Huang 3DEF , Zhu-Xin Wei 2DEF , Ya-Si Su 4DEF , Wen-Bin Dai 4ADG* , Lin Ruan 2ADEG*DOI: 10.12659/MSM.928185
Med Sci Monit 2020; 26:e928185
Table 1 Gene Ontology analysis (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis for immune-related up-regulated differentially genes and immune-related down-regulated differentially genes.
| Category | ID | Description | P. adjust | Q value | Count |
|---|---|---|---|---|---|
| GO-BP | GO: 0006958 | Complement activation, classical pathway | 3.57E-65 | 2.95E-65 | 46 |
| GO-BP | GO: 0002455 | Humoral immune response mediated by circulating immunoglobulin | 6.27E-62 | 5.17E-62 | 46 |
| GO-BP | GO: 0030449 | Regulation of complement activation | 2.89E-61 | 2.38E-61 | 47 |
| GO-BP | GO: 2000257 | Regulation of protein activation cascade | 3.59E-61 | 2.96E-61 | 47 |
| GO-CC | GO: 0072562 | Blood microparticle | 3.93E-29 | 3.70E-29 | 30 |
| GO-CC | GO: 0031093 | Platelet alpha granule lumen | 0.002598 | 0.002448 | 6 |
| GO-CC | GO: 0005788 | Endoplasmic reticulum lumen | 0.002598 | 0.002448 | 12 |
| GO-CC | GO: 0031983 | Vesicle lumen | 0.036346 | 0.034244 | 10 |
| GO-MF | GO: 0003823 | Antigen binding | 2.12E-88 | 1.81E-88 | 64 |
| GO-MF | GO: 0048018 | Receptor ligand activity | 2.65E-32 | 2.27E-32 | 45 |
| GO-MF | GO: 0030545 | Receptor regulator activity | 3.66E-31 | 3.13E-31 | 45 |
| GO-MF | GO: 0005125 | Cytokine activity | 5.77E-15 | 4.93E-15 | 20 |
| KEGG | hsa04060 | Cytokine-cytokine receptor interaction | 2.32E-22 | 2.09E-22 | 33 |
| KEGG | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 2.47E-11 | 2.23E-11 | 15 |
| KEGG | hsa04062 | Chemokine signaling pathway | 1.47E-06 | 1.33E-06 | 14 |
| KEGG | hsa04080 | Neuroactive ligand-receptor interaction | 1.88E-06 | 1.69E-06 | 18 |
| GO-BP | GO: 0019730 | Antimicrobial humoral response | 4.50E-08 | 3.61E-08 | 10 |
| GO-BP | GO: 0006959 | Humoral immune response | 2.16E-05 | 1.74E-05 | 11 |
| GO-BP | GO: 0009620 | Response to fungus | 3.92E-05 | 3.14E-05 | 6 |
| GO-BP | GO: 0031640 | Killing of cells of other organism | 6.00E-05 | 4.82E-05 | 6 |
| GO-CC | GO: 0035578 | Azurophil granule lumen | 1.25E-05 | 1.06E-05 | 7 |
| GO-CC | GO: 0005775 | Vacuolar lumen | 3.27E-05 | 2.76E-05 | 8 |
| GO-CC | GO: 0031983 | Vesicle lumen | 3.27E-05 | 2.76E-05 | 10 |
| GO-CC | GO: 0031012 | Extracellular matrix | 0.000352 | 0.000297 | 10 |
| GO-MF | GO: 0048018 | Receptor ligand activity | 1.81E-24 | 1.40E-24 | 28 |
| GO-MF | GO: 0030545 | Receptor regulator activity | 6.03E-24 | 4.65E-24 | 28 |
| GO-MF | GO: 0005125 | Cytokine activity | 1.04E-14 | 8.01E-15 | 15 |
| GO-MF | GO: 0008201 | Heparin binding | 1.07E-05 | 8.23E-06 | 8 |
| KEGG | hsa04060 | Cytokine-cytokine receptor interaction | 2.88E-12 | 2.72E-12 | 19 |
| KEGG | hsa04659 | Th17 cell differentiation | 0.02884 | 0.02727 | 5 |
| KEGG | hsa04630 | JAK-STAT signaling pathway | 0.02884 | 0.02727 | 6 |
| KEGG | hsa05321 | Inflammatory bowel disease (IBD) | 0.02884 | 0.02727 | 4 |
| Count – count of genes enriched in the category; BP – biological process; CC – cellular component; MF – molecular function. The deep blue area was based on the analysis of immune-related up-regulated differentially genes while the light blue area was based on the analysis of immune-related down-regulated differentially genes. | |||||